The Potential Benefits of Arming CD33 CAR Cytokine-Induced Killer Cells With CXCR4

The study was designed on the premise that the mechanisms used to support hematopoietic stem cells in their bone marrow niche can also support AML cells. By expressing CXCR4 on immune-effector cells, the authors hoped to position them closer to lucamic stem cells and increase the probability of achieving durable remissions in AML. They were able to demonstrate that enforcing CX CR4 expression on CD33 targeting CAR CIK cells enhances their homing to the bone marrow and improves their activity against AML.